We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Mycovia Pharmaceuticals, Inc. today announced it has submitted its New Drug Application (NDA) for oteseconazole, an oral antifungal product for the treatment of recurrent vulvovaginal candidiasis (RVVC).
Mycovia Pharmaceuticals has partnered with Jiangsu Hengrui Medicine to develop and commercialise its investigational drug VT-1161 (otesaconazole) in China.